Gonadorelin is the synthetic form of the body's own gonadotropin-releasing hormone (GnRH). It is one of the more mechanistically well-defined peptides in this library, because its target and physiology have been studied for decades. This monograph covers what it is, the pulsatile-versus-continuous distinction that defines its pharmacology, its documented clinical and diagnostic uses, and how to read a COA.
Chemical identity & structure.
Gonadorelin is a synthetic decapeptide (ten amino acids) with a sequence identical to endogenous GnRH (also called LHRH): pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. It is the native hormone itself, not a modified analog — which distinguishes it from the long-acting GnRH agonists (leuprolide, goserelin) and antagonists (cetrorelix, degarelix) that were engineered for sustained receptor occupancy. Its native structure gives it a very short half-life (on the order of minutes), which is central to how it behaves.
Mechanism of action.
Gonadorelin binds GnRH receptors on the gonadotrope cells of the anterior pituitary, stimulating release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn act on the gonads. The defining feature is that the direction of the effect depends entirely on the administration pattern. Delivered in brief pulses — mimicking the hypothalamus's own intermittent rhythm — it stimulates LH/FSH release; delivered continuously, it paradoxically downregulates and desensitizes the receptor, suppressing LH/FSH. This pulsatile-versus-continuous switch is the single most important pharmacological fact about the compound, and it is why the long-acting analogs are used for suppression while native gonadorelin's stimulatory use depends on pulsatile delivery.
Key research findings.
The pulsatile-GnRH mechanism is exceptionally well characterized, because it underpins normal reproductive physiology. In the published clinical/endocrine literature, pulsatile GnRH (gonadorelin) administration can induce puberty and restore fertility in people with congenital or hypothalamic hypogonadotropic hypogonadism — a use grounded in decades of endocrine research (evidence tier: established clinical literature). Gonadorelin has also been used diagnostically, as the stimulus in the GnRH stimulation test that probes pituitary gonadotrope responsiveness. The evidence is thinner for its off-label and community use as a short-acting alternative to hCG for maintaining testicular function during androgen protocols; that application is extrapolated from the pulsatile mechanism rather than supported by the same dedicated trial base, and should be read as such.
Regulatory & sourcing context.
Gonadorelin has a genuine regulatory history: it was marketed in the United States as Factrel (for diagnostic GnRH stimulation testing) and, as gonadorelin acetate delivered by pump (Lutrepulse), for pulsatile induction of ovulation in hypothalamic amenorrhea. Those branded products were largely discontinued in the US, and the peptide is today most commonly accessed through compounding pharmacies. It is a real, historically approved hormone — not a novel research chemical — but its current status is compounded rather than branded-FDA-approved.
Quality & COA considerations.
A credible COA should confirm the full decapeptide sequence and the C-terminal amide by mass spectrometry and report HPLC purity (≥98% is the practical benchmark), since short peptides are prone to deletion-sequence impurities. Because gonadorelin is the native GnRH sequence, identity confirmation matters — a COA should establish that the material is gonadorelin specifically and not a related GnRH analog. Sterility and endotoxin testing are relevant for any material used in a model involving injection.
Key references.
Young J, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev. 2019. https://doi.org/10.1210/er.2018-00116
Rohayem J, et al. Mini-Puberty, Physiological and Disordered. Endocr Rev. 2024. https://doi.org/10.1210/endrev/bnae003
Research-use note: This monograph is an educational summary of the published research and clinical literature on gonadorelin (synthetic GnRH). It describes what has been studied and reported — including the established clinical uses of the approved/compounded drug — and is not medical advice, a dosing recommendation, or guidance for personal use. Gonadorelin's stimulatory effect depends on pulsatile administration; continuous exposure produces the opposite, suppressive effect.
Great breakdown of pulsatile vs continuous dosing differences. Reminding us to separate native GnRH decapeptide from modified agonists is super helpful for accurate COA identification in lab work.
